255 related articles for article (PubMed ID: 17406029)
1. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens.
Daniele L; Macrì L; Schena M; Dongiovanni D; Bonello L; Armando E; Ciuffreda L; Bertetto O; Bussolati G; Sapino A
Mol Cancer Ther; 2007 Apr; 6(4):1223-9. PubMed ID: 17406029
[TBL] [Abstract][Full Text] [Related]
2. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.
Xu JM; Han Y; Duan HQ; Gao EM; Zhang Y; Liu XQ; Zhang JS; Toschi L; Galetta D; Azzariti A; Paradiso A
J Cancer Res Clin Oncol; 2009 Jun; 135(6):771-82. PubMed ID: 19020901
[TBL] [Abstract][Full Text] [Related]
3. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
Varella-Garcia M; Mitsudomi T; Yatabe Y; Kosaka T; Nakajima E; Xavier AC; Skokan M; Zeng C; Franklin WA; Bunn PA; Hirsch FR
J Thorac Oncol; 2009 Mar; 4(3):318-25. PubMed ID: 19247083
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
Dongiovanni D; Daniele L; Barone C; Dongiovanni V; Fissore C; Sapino A; Macrì L; Bussolati G; Buffoni L; Gaspari F; Grillo R; Birocco N; Addeo A; Ciuffreda L; Schena M
Lung Cancer; 2008 Jul; 61(1):73-81. PubMed ID: 18243402
[TBL] [Abstract][Full Text] [Related]
5. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
Han SW; Kim TY; Jeon YK; Hwang PG; Im SA; Lee KH; Kim JH; Kim DW; Heo DS; Kim NK; Chung DH; Bang YJ
Clin Cancer Res; 2006 Apr; 12(8):2538-44. PubMed ID: 16638863
[TBL] [Abstract][Full Text] [Related]
6. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
Cappuzzo F; Varella-Garcia M; Shigematsu H; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Gregorc V; Toschi L; Franklin WA; Crino L; Gazdar AF; Bunn PA; Hirsch FR
J Clin Oncol; 2005 Aug; 23(22):5007-18. PubMed ID: 16051952
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.
Pinter F; Papay J; Almasi A; Sapi Z; Szabo E; Kanya M; Tamasi A; Jori B; Varkondi E; Moldvay J; Szondy K; Keri G; Dominici M; Conte P; Eckhardt S; Kopper L; Schwab R; Petak I
J Mol Diagn; 2008 Mar; 10(2):160-8. PubMed ID: 18258923
[TBL] [Abstract][Full Text] [Related]
8. Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.
Tokumo M; Toyooka S; Ichihara S; Ohashi K; Tsukuda K; Ichimura K; Tabata M; Kiura K; Aoe M; Sano Y; Date H; Shimizu N
Lung Cancer; 2006 Jul; 53(1):117-21. PubMed ID: 16730855
[TBL] [Abstract][Full Text] [Related]
9. Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer.
Simone G; Mangia A; Malfettone A; Rubini V; Siciliano M; Di Benedetto A; Terrenato I; Novelli F; Mottolese M
J Exp Clin Cancer Res; 2010 Sep; 29(1):125. PubMed ID: 20843314
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer.
Sone T; Kasahara K; Kimura H; Nishio K; Mizuguchi M; Nakatsumi Y; Shibata K; Waseda Y; Fujimura M; Nakao S
Cancer; 2007 May; 109(9):1836-44. PubMed ID: 17387741
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer.
Sasaki H; Endo K; Okuda K; Kawano O; Kitahara N; Tanaka H; Matsumura A; Iuchi K; Takada M; Kawahara M; Kawaguchi T; Yukiue H; Yokoyama T; Yano M; Fujii Y
J Cancer Res Clin Oncol; 2008 May; 134(5):569-77. PubMed ID: 17932690
[TBL] [Abstract][Full Text] [Related]
12. Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.
Pugh TJ; Bebb G; Barclay L; Sutcliffe M; Fee J; Salski C; O'Connor R; Ho C; Murray N; Melosky B; English J; Vielkind J; Horsman D; Laskin JJ; Marra MA
BMC Cancer; 2007 Jul; 7():128. PubMed ID: 17626639
[TBL] [Abstract][Full Text] [Related]
13. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ; Bell DW; Sordella R; Gurubhagavatula S; Okimoto RA; Brannigan BW; Harris PL; Haserlat SM; Supko JG; Haluska FG; Louis DN; Christiani DC; Settleman J; Haber DA
N Engl J Med; 2004 May; 350(21):2129-39. PubMed ID: 15118073
[TBL] [Abstract][Full Text] [Related]
14. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.
Tokumo M; Toyooka S; Kiura K; Shigematsu H; Tomii K; Aoe M; Ichimura K; Tsuda T; Yano M; Tsukuda K; Tabata M; Ueoka H; Tanimoto M; Date H; Gazdar AF; Shimizu N
Clin Cancer Res; 2005 Feb; 11(3):1167-73. PubMed ID: 15709185
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
Asahina H; Yamazaki K; Kinoshita I; Sukoh N; Harada M; Yokouchi H; Ishida T; Ogura S; Kojima T; Okamoto Y; Fujita Y; Dosaka-Akita H; Isobe H; Nishimura M
Br J Cancer; 2006 Oct; 95(8):998-1004. PubMed ID: 17047648
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.
Dziadziuszko R; Witta SE; Cappuzzo F; Park S; Tanaka K; Danenberg PV; Barón AE; Crino L; Franklin WA; Bunn PA; Varella-Garcia M; Danenberg KD; Hirsch FR
Clin Cancer Res; 2006 May; 12(10):3078-84. PubMed ID: 16707605
[TBL] [Abstract][Full Text] [Related]
17. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.
Hirsch FR; Varella-Garcia M; Cappuzzo F; McCoy J; Bemis L; Xavier AC; Dziadziuszko R; Gumerlock P; Chansky K; West H; Gazdar AF; Crino L; Gandara DR; Franklin WA; Bunn PA
Ann Oncol; 2007 Apr; 18(4):752-60. PubMed ID: 17317677
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
19. Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma.
Sholl LM; John Iafrate A; Chou YP; Wu MT; Goan YG; Su L; Huang YT; Christiani DC; Chirieac LR
Mod Pathol; 2007 Oct; 20(10):1028-35. PubMed ID: 17673923
[TBL] [Abstract][Full Text] [Related]
20. Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer.
Oshita F; Matsukuma S; Yoshihara M; Sakuma Y; Ohgane N; Kameda Y; Saito H; Yamada K; Tsuchiya E; Miyagi Y
Br J Cancer; 2006 Oct; 95(8):1070-5. PubMed ID: 17047654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
